Drugs / mRNA-2736
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05918250 | Aug 2023 → May 2026 | refractory plasma cell neoplasm | ModernaTX, Inc. | Withdrawn | No outcome recorded Stop: Business |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | mRNA-2736 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05918250 ↗ |
| Route | Intravenous | “mRNA-2736, administered intravenously (IV)” NCT05918250 ↗ |